MiRus has raised US$65 million in a new funding round that will help the firm grow its spinal and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoRe).
The round was led by Mammoth Scientific and multi-generational family offices who have supported MiRus from its inception.
Jay Yadav, founder and CEO of MiRus, said: “We are delighted to see the validation and excitement around our Rhenium-based materials since FDA clearance of the first MoRe-based spine implant in 2019.
“This funding will allow us to meet the overwhelming demand from spine surgeons across the country for our highly differentiated products and procedural solutions using the MoRe superalloy and continue our planned expansion into other important areas including structural heart disease.”
Tommy Martin, CEO of venture capital firm Mammoth Scientific, added: “We are excited to partner with the blue chip team at MiRus and see the application of its disruptive technology platform across medical implants.
“MiRus has already revolutionised spine surgery and has a remarkable pipeline for groundbreaking products in complex extremity surgery and transcatheter aortic valve replacement.”